SIMD 2022 symposium: Advancing the diagnosis and management of a rare neurometabolic disorder: A focus on AADC deficiency
This satellite symposium, presented at the 2022 SIMD Annual Meeting in Orlando, Florida, focuses on the diagnosis and management of aromatic L-amino acid decarboxylase (AADC) deficiency
Learn about the biochemical tests to diagnose AADC deficiency
Understand the variants in the DDC gene that are associated with AADC deficiency and ways to improve their interpretation
Find out about the latest clinical trial experience of an investigational gene replacement therapy for the treatment of AADC deficiency
This symposium was developed and funded by PTC Therapeutics at SIMD 2022. It was not part of the official program of SIMD 2022.
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2200063 | July 2022
Sign in or register to access exclusive content on this site